Last reviewed · How we verify
prednisone and cyclophosphamide
Prednisone suppresses immune and inflammatory responses while cyclophosphamide acts as an alkylating agent to kill rapidly dividing cells, together providing immunosuppression and cytotoxic effects.
Prednisone suppresses immune and inflammatory responses while cyclophosphamide acts as an alkylating agent to kill rapidly dividing cells, together providing immunosuppression and cytotoxic effects. Used for Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis), Hematologic malignancies and lymphomas, Severe refractory autoimmune conditions.
At a glance
| Generic name | prednisone and cyclophosphamide |
|---|---|
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Corticosteroid + Alkylating agent combination |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Prednisone is a corticosteroid that inhibits inflammatory cytokine production and immune cell activation. Cyclophosphamide is an alkylating chemotherapy agent that cross-links DNA and causes cell death, particularly affecting rapidly dividing lymphocytes. This combination leverages both immunosuppressive and cytotoxic mechanisms to treat autoimmune and hematologic conditions.
Approved indications
- Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis)
- Hematologic malignancies and lymphomas
- Severe refractory autoimmune conditions
Common side effects
- Infection
- Myelosuppression
- Hemorrhagic cystitis
- Nausea and vomiting
- Immunosuppression-related complications
- Secondary malignancy
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: